Last reviewed · How we verify
cetuximab + cisplatin + vinorelbine
Cetuximab targets the epidermal growth factor receptor (EGFR), while cisplatin and vinorelbine work by interfering with DNA replication and cell division.
Cetuximab targets the epidermal growth factor receptor (EGFR), while cisplatin and vinorelbine work by interfering with DNA replication and cell division. Used for Metastatic colorectal cancer, Head and neck cancer.
At a glance
| Generic name | cetuximab + cisplatin + vinorelbine |
|---|---|
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Drug class | Antineoplastic agents |
| Target | EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cetuximab is a monoclonal antibody that binds to EGFR, preventing it from interacting with its ligands and thereby inhibiting tumor growth. Cisplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, which interfere with DNA replication and transcription, leading to cell death. Vinorelbine is a vinca alkaloid that binds to tubulin, preventing microtubule formation and thereby inhibiting cell division.
Approved indications
- Metastatic colorectal cancer
- Head and neck cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Vomiting
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy (PHASE3)
- Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer (PHASE2)
- Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC) (PHASE2)
- Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer (PHASE2)
- Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic (PHASE2)
- Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) (PHASE3)
- Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) (PHASE3)
- Phase I Cetuximab and Concurrent Radio-chemotherapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: